SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
SUPERNUS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$39.84+1.96 (+5.17%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Supernus Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.32B | $197.05M |
| Enterprise Value | $2.14B | $106.56M |
| PS Ratio | 2.79 | 3.93 |
| PB Ratio | 2.25 | 2.14 |
| P/TBV Ratio | 5.24 | 2.46 |
| P/FCF Ratio | 123.27 | 18.25 |
| P/OCF Ratio | 116.31 | 13.78 |
Enterprise value
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.57 | 2.69 |
| EV / FCF | 113.69 | 21.02 |
Income (trailing twelve months)
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $830.44M | $57.94M |
| Gross Profit | $731.41M | $90.47M |
| Operating Income | -$130.46M | -$21.44M |
| Pretax Income | -$123.47M | -$14.45M |
| Net Income | -$109.89M | -$22.46M |
| EBITDA | -$78.42M | -$16.91M |
| EPS (Diluted) | -$1.92 | -$0.83 |
Margins
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 88.1% | 52.3% |
| Operating Margin | -15.7% | -44.5% |
| Pretax Margin | -14.9% | -13.0% |
| Profit Margin | -13.2% | -39.2% |
| EBITDA Margin | -9.44% | -31.3% |
| FCF Margin | 2.26% | -8.85% |
Returns
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -10.5% | -53.1% |
| Return on Assets (ROA) | -7.82% | -41.0% |
| Return on Invested Capital (ROIC) | -11.6% | -32.0% |
| Return on Capital Employed (ROCE) | -12.1% | -37.8% |
Growth
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 24.9% | 6.01% |
| Net Income Growth (YoY) | -270.4% | -37.7% |
| EPS Growth (YoY) | -267.0% | -29.2% |
| FCF Growth (YoY) | -89.9% | 2.34% |
| Revenue Growth (3Y CAGR) | 2.52% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.68% | 6.42% |
Balance sheet
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $179.95M | $62.42M |
| Net Cash (Debt) | $179.95M | $15.68M |
| Net Cash Per Share | $3.10 | $0.65 |
| Equity (Book Value) | $1.03B | $48.79M |
| Book Value Per Share | $17.74 | $1.36 |
| Tangible Book Value | $442.34M | $23.06M |
| Working Capital | $376.12M | $75.77M |
Financial position
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.08 | 3.30 |
| Quick Ratio | 1.13 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $19.91M | -$12.35M |
| Capital Expenditures | -$1.12M | -$1.06M |
| Free Cash Flow | $18.79M | -$20.28M |
| FCF Per Share | $0.32 | -$0.41 |
Efficiency
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.59 | 0.38 |
| Inventory Turnover | 1.31 | 2.67 |
| Revenue Per Employee | $1.07M | $398.96K |
| Profits Per Employee | -$141.24K | -$732.08K |
| Employee Count | 778 | 73 |
Dividends and yields
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -4.75% | -21.2% |
| FCF Yield | 0.81% | -7.64% |
| Buyback Yield | -2.16% | -0.58% |
| Shareholder Yield | -2.16% | 0.00% |
Shares
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 58,127,000 | 59,128,900 |
| Shares Change (YoY) | 2.08% | 11.1% |
| Shares Change (QoQ) | 0.21% | 0.54% |
| Float | 49,349,600 | 48,744,500 |
| Shares Held by Insiders | 15.1% | 11.8% |
| Shares Held by Institutions | 103.8% | 59.4% |
Taxes
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$13.58M | $91.50K |
Scores
| Measure | Supernus Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 4.55 | 0.10 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -2.54 | -2.62 |
Calculated by StockData from Supernus Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.